The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...
(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...